Quince Therapeutics (QNCX) Competitors $1.58 -0.05 (-3.07%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.02 (+1.58%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. ZYBT, ADCT, BNTC, FDMT, INBX, CADL, LRMR, RCKT, AMRN, and ALDXShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Rocket Pharmaceuticals (RCKT), Amarin (AMRN), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Zhengye Biotechnology ADC Therapeutics Benitec Biopharma 4D Molecular Therapeutics Inhibrx Biosciences Candel Therapeutics Larimar Therapeutics Rocket Pharmaceuticals Amarin Aldeyra Therapeutics Quince Therapeutics (NASDAQ:QNCX) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Is QNCX or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -187.49% -42.47% Zhengye Biotechnology N/A N/A N/A Does the media prefer QNCX or ZYBT? In the previous week, Zhengye Biotechnology had 4 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for Zhengye Biotechnology and 2 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.49 beat Zhengye Biotechnology's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer QNCX or ZYBT? Quince Therapeutics currently has a consensus target price of $8.14, suggesting a potential upside of 415.37%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger valuation & earnings, QNCX or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Quince Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.09-1.45Zhengye Biotechnology$25.53M14.78$1.55MN/AN/A Do insiders & institutionals hold more shares of QNCX or ZYBT? 30.8% of Quince Therapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryQuince Therapeutics beats Zhengye Biotechnology on 7 of the 12 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.86M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.4520.9030.1925.84Price / SalesN/A386.36473.64122.75Price / CashN/A43.2325.7828.79Price / Book2.299.649.425.99Net Income-$56.83M-$54.08M$3.27B$265.29M7 Day Performance-5.39%2.62%2.05%2.53%1 Month Performance-14.59%4.05%3.58%0.93%1 Year Performance139.39%9.48%30.09%18.70% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.8156 of 5 stars$1.58-3.1%$8.14+415.4%+147.0%$84.86MN/A-1.4560ZYBTZhengye BiotechnologyN/A$7.84+4.4%N/AN/A$354.22M$25.53M0.00278ADCTADC Therapeutics1.7625 of 5 stars$3.24+3.5%$7.75+139.2%+3.1%$352.12M$70.84M-2.06310High Trading VolumeBNTCBenitec Biopharma1.3787 of 5 stars$12.71-2.3%$26.00+104.6%+43.5%$341.52M$80K-8.4220FDMT4D Molecular Therapeutics2.0066 of 5 stars$7.27+0.1%$30.40+318.2%-52.6%$339.06M$40K-2.06120INBXInhibrx Biosciences1.3783 of 5 stars$23.87+2.3%N/A+87.4%$337.95M$200K-2.26166News CoveragePositive NewsAnalyst ForecastCADLCandel Therapeutics2.3312 of 5 stars$5.96-2.1%$22.00+269.1%+4.8%$334.31M$120K-8.6460LRMRLarimar Therapeutics2.3957 of 5 stars$3.90-2.7%$18.43+372.5%-50.3%$331.94MN/A-2.5030RCKTRocket Pharmaceuticals4.9315 of 5 stars$3.03-0.7%$16.33+439.1%-80.4%$329.11MN/A-1.21240Analyst RevisionAMRNAmarin0.2962 of 5 stars$16.17+3.3%$12.00-25.8%+27.1%$324.07M$228.61M-4.41360ALDXAldeyra Therapeutics1.8336 of 5 stars$5.44+0.9%$9.50+74.6%+4.3%$322.84MN/A-6.4010 Related Companies and Tools Related Companies Zhengye Biotechnology Alternatives ADC Therapeutics Alternatives Benitec Biopharma Alternatives 4D Molecular Therapeutics Alternatives Inhibrx Biosciences Alternatives Candel Therapeutics Alternatives Larimar Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Amarin Alternatives Aldeyra Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access